DDInter1085 DDInter899
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Lomitapide {u} (Compound) resembles {v} (Compound) Antrafenine
Lomitapide {u} (Compound) binds {v} (Gene) CYP3A4
Lomitapide {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Lomitapide {u} (Compound) causes {v} (Side Effect) Xanthoma
Lomitapide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Lomitapide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Terbinafine
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Lomitapide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fexofenadine
Lomitapide (Compound) resembles Antrafenine (Compound)
Lomitapide (Compound) binds CYP3A4 (Gene)
Lomitapide (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Lomitapide (Compound) causes Xanthoma (Side Effect)
Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Lomitapide may lead to a major life threatening interaction when taken with Terbinafine
Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Lomitapide (Compound) resembles Fexofenadine (Compound) and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine